PAPER Chen L, Dodge HH, Asgari M
SEARCH RESULTS
333 RESULTS
PAPER Chang Y, Yao Y, Ma R, Wang Z, Hu J, Wu Y, Jiang X, Li L, Li G
Dl-3-n-Butylphthalide Reduces Cognitive Deficits and Alleviates Neuropathology in P301S Tau Transgenic Mice.
Front Neurosci. 2021;15:620176. Epub 2021 Feb 10 PubMed: 33642981PAPER Zhou X, Fu AK, Ip NY
APOE signaling in neurodegenerative diseases: an integrative approach targeting APOE coding and noncoding variants for disease intervention.
Curr Opin Neurobiol. 2021 Aug;69:58-67. Epub 2021 Feb 26 PubMed: 33647674Randall Schommer
Joliet, United States
PAPER Sciamanna G, Ponterio G, Tassone A, Maltese M, Madeo G, Martella G, Poli S, Schirinzi T, Bonsi P, Pisani A
Negative allosteric modulation of mGlu5 receptor rescues striatal D2 dopamine receptor dysfunction in rodent models of DYT1 dystonia.
Neuropharmacology. 2014 Oct;85:440-50. Epub 2014 Jun 19 PubMed: 24951854PAPER Arsova A, Møller TC, Vedel L, Hansen JL, Foster SR, Gregory KJ, Bräuner-Osborne H
Detailed In Vitro Pharmacological Characterization of Clinically Tested Negative Allosteric Modulators of the Metabotropic Glutamate Receptor 5.
Mol Pharmacol. 2020 Jul;98(1):49-60. Epub 2020 May 1 PubMed: 32358164PAPER Bennett KA, Sergeev E, MacSweeney CP, Bakker G, Cooper AE
Understanding exposure-receptor occupancy relationships for metabotropic glutamate receptor 5 (mGlu5) negative allosteric modulators across a range of pre-clinical and clinical studies.
J Pharmacol Exp Ther. 2021 Feb 4; PubMed: 33541889PAPER Rascol O, Fox S, Gasparini F, Kenney C, Di Paolo T, Gomez-Mancilla B
Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias.
Parkinsonism Relat Disord. 2014 Sep;20(9):947-56. Epub 2014 May 14 PubMed: 24951359PAPER Wang WW, Zhang XR, Zhang ZR, Wang XS, Chen J, Chen SY, Xie CL
Effects of mGluR5 Antagonists on Parkinson's Patients With L-Dopa-Induced Dyskinesia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Front Aging Neurosci. 2018;10:262. Epub 2018 Sep 11 PubMed: 30271338Asgeir Bjornsson
Cornelis Blauwendraat
Bethesda, United States
Alejandro Martínez Carrasco
Ph.D. studentLondon, United Kingdom
Dipraglurant
THERAPEUTICS 6-Fluoro-2-[4-(2-pyridinyl)-3-butyn-1-yl]imidazo[1,2-a]pyridine Addex Therapeutics ADX48621 Small Molecule Other Neurotransmitters Addex completed a Phase 2a trial for Parkinson’s Disease LID in 2012. Conducted in the U.S. and Europe, it enrolled 76 peopl
J.P.H. Burbach
University Medical Center UtrechtUtrecht, Netherlands
Sopan Nangare
Research Scholar, ICMR, IndiaShirpur, Dhule, India
Current Filters
- Date Range : Feb 2021 to Mar 2021 x